Filling an Unmet Medical Need in the Veteran Population: First-Line Treatment of Metastatic NSCLC in Those Without Actionable Molecular Subtypes


Julia K. Rotow, MD
Medical Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA


Shayma Kazmi, MD
Medical Oncologist
Penn Medicine
Cherry Hill, NJ


This program will discuss tumorigenesis in advanced non-small cell lung cancer (NSCLC) and the mechanism of actions of checkpoint inhibitors, the latest clinical data describing the efficacy and safety of first-line use of PD-1 inhibitor therapy, alone and in combination, and the use of immunotherapy in the first-line treatment of NSCLC with no actionable mutations.


This activity is designed to meet the educational needs of medical oncologists, oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to maintain an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies in the Department of Veteran Affairs.


Upon the completion of this program, attendees should be able to:

  • Describe the effects that immune checkpoint inhibitors have on the pathophysiology of NSCLC
  • Evaluate recent immunotherapy clinical trials data in the first-line treatment of patients with advanced NSCLC
  • Explain the application of clinical practice guidelines in the management of Veterans with advanced NSCLC with no targetable mutations


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Purpose: This program would be beneficial for nurses involved in the care of patients with NSCLC.
CNE Credits: 1.0 ANCC Contact Hour.


Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


Julia K. Rotow, MD, reports that she has received consulting fees from AstraZeneca, AbbVie, Gritstone, Lilly, Takeda Pharmaceuticals and Sanofi-Genzyme. She has also been contracted for research (Principal Investigator – active or pending) from AstraZeneca, Blueprint, EpimAb, BioAtla, Bicycle Therapeutics, AbbVie, and Lilly, and has received honoraria/other royalties from AstraZeneca, Pfizer, Merck, Janssen, Sanofi-Genzyme, Lilly and Jazz.

Shayma Kazmi, MD, reports that she is a consultant for Foundation Medicine.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Sylvia Hanna, MD, Medical Director for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
  • Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.


There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.


Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at


Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASE DATE: October 07,  2022

EXPIRATION DATE: October 07, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scientific Council

Neil M. Bressler, MD

James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
Baltimore, MD

A. Paul Chous, MA, OD, FAAO

Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Tacoma, WA

Steven Ferrucci, OD, FAAO

Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Sepulveda, CA

Julia A. Haller, MD

Wills Eye Hospital
Philadelphia, PA

Allen C. Ho, MD, FACS

Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Philadelphia, PA

Charles C. Wykoff, MD, PhD

Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
Houston, TX



Clinician Scientific & Educational Resources

The RELIEF Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for retinopathy of prematurity (ROP). Click on one of the options below to learn more about ROP.

Patient Toolkit

Patient Toolkit

Read more

What exactly is NSCLC?

What exactly is NSCLC?

Read more

What symptoms can NSCLC cause?

What symptoms can NSCLC cause?

Read more

How is NSCLC treated according to staging?

How is NSCLC treated according to staging?

Read more

How is early NSCLC treated with surgery or SBRT?

How is early NSCLC treated with surgery or SBRT?

Read more

When is chemotherapy used in NSCLC?

When is chemotherapy used in NSCLC?

Read more

When is radiation used in NSCLC?

When is radiation used in NSCLC?

Read more

When is immunotherapy used in NSCLC?

When is immunotherapy used in NSCLC?

Read more

When is targeted therapy used in NSCLC?

When is targeted therapy used in NSCLC?

Read more

Online resources

Online resources

Read more
This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2019 | ROP Relief | All Rights Reserved | Website by Divigner